ChromaDex Corporation (CDXC) News

Form 8-K - Current report

ChromaDex Appoints Ozan Pamir as Chief Financial Officer

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces...

ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics

U.S. FDA-registered 503B outsourcing facility, Wells Pharma of Houston, will compound and distribute Niagen...

ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions

Commemorating a quarter of a century with an exclusive 25% off lifelong subscription on Tru Niagen® ChromaDex Corp. (NASDAQ:CDXC), the global...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+

One of the most robust forms of intellectual property protection, a composition of matter patent grants ChromaDex exclusive rights to the...

ChromaDex Corporation Reports Second Quarter 2024 Financial Results

Total net sales of $22.7 million, up 12% year-over-year, gross margin of 60.2%, lower operating expenses, resulting in approximately breakeven...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]